A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.
bioRxiv · 2025
Last updated 2026-05-28A study examined how cagrilintide, a potential weight-loss drug similar to amylin, affects brainstem cells in rats, mice, and monkeys. In rats, which respond well to the drug, cagrilintide caused long-term changes in certain brain cells, including increased activity in cells linked to prolactin releasing hormone. However, in mice, which respond poorly to cagrilintide over time, these changes did not occur.
AI summary of the abstract below.
| Journal | bioRxiv, 2025 |
|---|---|
| Citations | 9 |
| Relative citation ratio | 3.64 |
| Molecules | cagrilintide |
| Conditions studied | Obesity |
Abstract
Amylin analogs, including potential anti-obesity therapies like cagrilintide, act on neurons in the brainstem dorsal vagal complex (DVC) that express calcitonin receptors (CALCR). These receptors, often combined with receptor activity-modifying proteins (RAMPs), mediate the suppression of food intake and body weight. To understand the molecular and neural mechanisms of cagrilintide action, we used single-nucleus RNA sequencing to define 89 cell populations across the rat, mouse, and non-human primate caudal brainstem. We then integrated spatial profiling to reveal neuron distribution in the rat DVC. Furthermore, we compared the acute and long-term transcriptional responses to cagrilintide across DVC neurons of rats, which exhibit strong cagrilintide responsiveness, and mice, which respond poorly to cagrilintide over the long term. We found that cagrilintide promoted long-term transcriptional changes, including increased prolactin releasing hormone ( expression, in the nucleus of the solitary tract (NTS) cells in rats, but not in mice, suggesting the importance of NTS cells for sustained weight loss. Indeed, activating rat area postrema cells briefly reduced food intake but failed to decrease food intake or body weight over the long term. Overall, these results not only provide a cross-species and spatial atlas of DVC cell populations but also define the molecular and neural mediators of acute and long-term cagrilintide action.
Verbatim abstract via PubMed 39868309 ↗
Related research
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Development of Cagrilintide, a Long-Acting Amylin Analogue.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Cagrilintide plus semaglutide for obesity management.